JCV

Need to Know: What Is the JC Virus?

Editor’s note: “Need to Knowā€ is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Does PML worry you?” from April 18. The world of multiple sclerosis (MS)…

Immune System Activation Induced by Filgrastim Likely Beneficial for Patients with Tysabri-associated PML, Study Says

Immune system activation induced by filgrastim may be beneficial for patients with progressive multifocal leukoencephalopathy associated with the use of Tysabri (natalizumab), without worsening multiple sclerosis (MS) progression, a study says. The study with that finding, “Treatment of natalizumabā€associated PML with filgrastim,” was published in…

#AANAM – Research Suggests Extended Interval Dosing of Tysabri Can Decrease Risk of PML

New data suggests that treatment withĀ TysabriĀ (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk ofĀ progressive multifocal leukoencephalopathyĀ (PML) in patients with multiple sclerosis (MS), compared with the standard interval dosing. The data was presented byĀ Lana Zhovtis Ryerson, MD, on May 7 at the 2019Ā …

Switching from Tysabri to Aubagio Can Help Lower Relapse Risk in MS Patients, Phase 4 Trial Shows

Stable patients with multiple sclerosis (MS) who transition from Tysabri (natalizumab) treatment toĀ Aubagio (teriflunomide) have a lower relapse risk, a new study shows. The study, ā€œReducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy,ā€…

Good News for Tysabri Users Who Are JCV Positive

One of the many disease-modifying therapies (DMTs) that I’ve been on over the many years of my treatment for MS is Tysabri (natalizumab). It worked well, holding the progression of my MS at bay for the several years that I received the infusions. I’d probably still be on it…

Tysabri Shows Long-term Safety, Efficacy in Japanese RRMS Patients, Study Shows

A recentĀ study has found Tysabri (natalizumab) treatment for two years to beĀ efficient and safe in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). The study, ā€œSafety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial,ā€ appearedĀ in the journal…

Tysabri’s Success in Impairing the Immune System in RRMS May Be Source of Its Problems

Although Tysabri (natalizumab) is a highly effective in treatingĀ patients with relapsing-remitting multiple sclerosis (RRMS), some may developĀ progressive multifocal leukoencephalopathy (PML). According to a new study,Ā this occurs because TysabriĀ impairs immune surveillance in the central nervous system and reactivates the latentĀ John Cunningham polyomavirus (JCV). The study, “Natalizumab Affects…